Market Scope. XXXXXX is hereby designated an authorized non-exclusive distributor of the Products in the following markets: [***] (collectively, the "Yield"). Specifically included within the Field are research activities in the [***] . Specifically excluded from the Field are[***] (including applications subject to regulatory labeling including "For Investigational Use Only" or "For Research Use Only"), [***] Paragraphs 2(c), 2(e), 2(t), 2(g) 2(h) and 2(i) of the Distribution Agreement are deleted in their entirety. Paragraph 3 of the Distribution Agreement is deleted in its entirety and replaced by the following
Market Scope. As previously described, the provision of cancer treatment is a significant and growing market. According to the American Cancer Society, the estimated number of cancer cases diagnosed annually in the United States (excluding certain skin cancers) increased from approximately 782,000 in 1980 to approximately 1.2 million in 1994 (an increase of 53%), due largely to a growing and aging population. As a result of these forces, over eight million Americans alive today have been diagnosed with cancer. Lung cancer has driven this growth, increasing 450% among women and 100% among men since the 1950's. The Company anticipates that these trends will continue and that the number of cancer patients, and the demand for oncology services, will continue to increase. It is estimated that the market for oncology pharmaceuticals will reach $1 billion by the year 2002. The most common type of cancer is prostate cancer, with approximately 200,000 new cases diagnosed in 1994. In the past two years prostate overtook breast cancer, which was second in 1994 with 182,000 new cases; lung was third with 172,000, and colorectal was fourth with 142,000. Cancer is second only to heart disease as the leading cause of death in the United States, and close to one quarter of all deaths in the U.S. are due to cancer. Deaths have increased significantly, led by lung cancer which accounted for 153,000 deaths in 1994. Melanoma and myeloma have also increased significantly, although not nearly to this extent. Cancers for which mortality has decreased the most are cervical, uterine, stomach and Hodgkin's. The cost of treating cancer patients has also increased - currently, the cost of cancer exceeds that of any other disease group in the U.S., surpassing even cardiovascular disease. This escalation is expected to continue. The National Cancer Institute estimates that total cancer costs (including lost productivity and mortality costs) were approximately $104 billion in 1994, with direct medical costs constituting approximately $35 billion of that total. Direct costs have increased 61% since 1985, and nearly 170% from 1975. The Company believes that these direct medical costs associated with cancer will increase more rapidly than those associated with most other diseases due to the growth in number of cancer patients and the high cost of new therapies. As a result, the market for oncology pharmaceuticals is estimated to be $1 billion by the year 2002.
